ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anti-citrullinated Protein Autoantibodies (ACPAs)"

  • Abstract Number: 0440 • ACR Convergence 2021

    Association Between Rheumatic Autoantibody Positivity and Immune-related Adverse Events

    Kristen Mathias1, Marco Lopez Velazquez1 and Pankti Reid2, 1University of Chicago, Chicago, IL, 2University of Chicago Medical Center, Chicago, IL

    Background/Purpose: The advent of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy; however, their use can lead to off-target toxicities called immune-related adverse events (irAEs)…
  • Abstract Number: 0461 • ACR Convergence 2021

    Plasmablast-derived Autoantibodies from Individuals At-risk for RA That Target RA-relevant Antigens Are Polyreactive with Arthritogenic Bacteria

    Meagan Chriswell1, Jennifer Seifert2, Michelle Bloom3, Cliff Rims4, Marie Feser5, Kevin Deane6, Jill Norris7, Eddie James8, Jane Buckner9, William Robinson10, V. Michael Holers11 and Kristine Kuhn12, 1UC Denver SOM, Denver, CO, 2University of Colorado School of Medicine, Littleton, CO, 3Stanford University, Redwood City, CA, 4Benaroya Research Institute, Seattle, WA, 5University of Colorado Denver, Aurora, CO, 6University of Colorado Denver, Denver, CO, 7Colorado School of Public Health, Aurora, CO, 8Benaroya Research Institute at Virginia Mason, Monroe, WA, 9Benaroya Research Institute at Virginia Mason, Seattle, WA, 10Stanford University, Palo Alto, CA, 11University of Colorado, Denver, CO, 12University of Colorado Anschutz Medical Campus, Aurora, CO

    Background/Purpose: Circulating autoantibodies like ACPA frequently develop years before symptoms of RA, during which the individual is at-risk for disease. Several lines of evidence suggest…
  • Abstract Number: 0790 • ACR Convergence 2021

    Unraveling Heterogeneity Within ACPA-negative Rheumatoid Arthritis; The Subgroup of Patients with a Strong Clinical and Serological Response to Initiation of DMARD-treatment Favor Disease Resolution

    Marloes Verstappen1, Hanna van Steenbergen2, Pascal de Jong3 and Annette H.M van der Helm-van Mil1, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden Univeristy Medical Center, Leiden, Netherlands, 3Erasmus MC, Hendrik Ido Ambacht, Netherlands

    Background/Purpose: Rheumatoid arthritis (RA) is a heterogeneous disease, especially ACPA-negative-RA. This is reflected by differences in long-term outcomes, ranging from refractory RA to sustained-DMARD-free-remission(SDFR; sustained…
  • Abstract Number: 0007 • ACR Convergence 2021

    Divergent Reactivities of Rheumatoid Factors and Anti-Modified Protein Antibodies Converge on IgG Epitopes

    Aisha Mergaert1, Zihao Zheng1, Michael Denny1, Maya Amjadi1, Janna Bashar1, Michael Newton1, Vivianne Malmström2, Caroline Grönwall2, Sara McCoy1 and Miriam Shelef1, 1University of Wisconsin, Madison, WI, 2Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) patients often develop rheumatoid factors (RFs), antibodies that bind IgG Fc, and anti-modified protein antibodies (AMPAs), multi-reactive autoantibodies that commonly bind…
  • Abstract Number: 0813 • ACR Convergence 2021

    Improvement in Clinical Disease Activity and Patient-Reported Outcomes After 6 Months of Treatment with Abatacept, Stratified by Line of Therapy, in Patients with RA: Results from a Large, US, National Observational Study

    Leslie Harrold1, Keith Wittstock2, Sheila Kelly2, Sang Hee Park2, Xue Han2, Ying Shan1, Carla Roberts-Toler1, Nicole Middaugh1 and Vadim Khaychuk2, 1CorEvitas, LLC, Waltham, MA, 2Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: RA is more responsive to treatment in the early stages of disease, and early treatment may lead to better long-term outcomes.1,2 Data on the…
  • Abstract Number: 0012 • ACR Convergence 2021

    A Novel Mechanism Linking Mucosal Bacteria with Autoantibody Responses in RA: Acetylated Bacterial Lysate as a Model Antigen

    Mikhail Volkov, Arieke Kampstra, Karin van Schie, Joanneke Kwekkeboom, Tom WJ Huizinga, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Rheumatoid arthritis (RA) is characterized by autoantibodies against post-translationally modified proteins (AMPA) such as citrullinated, carbamylated and acetylated proteins. Importantly, these antibodies are highly…
  • Abstract Number: 1014 • ACR Convergence 2021

    Enhanced Expression of Rheumatoid Arthritis Related Autoantibodies Following Airborne Endotoxin Exposure in the Setting of Collagen-Induced Arthritis

    Ted Mikuls1, Rohit Gaurav1, Geoffrey Thiele1, Bryant England1, Madison Wolfe1, Brianna Shaw1, Kristina Bailey1, Amy Nelson1, Michael Duryee1, Carlos Hunter1, Debra Romberger1, Dana Ascherman2 and Jill Poole1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: In addition to inflammatory arthritis, collagen-induced arthritis (CIA) recapitulates cardinal features of rheumatoid arthritis (RA) including autoreactive T cells, peptidyl-arginine deiminase expression, and citrullination…
  • Abstract Number: 0021 • ACR Convergence 2021

    Unique Alterations in Circulating T Peripheral Helper Cells Are Found in Different Ethnic Groups of ACPA+ Individuals Both At-risk for and with Classified RA

    Hideto Takada1, Yuko Okamoto2, Yasuhiro Katsumata3, Jennifer Seifert4, Kristen Demoruelle5, Jill Norris6, Kevin Deane7, Masayoshi Harigai3 and V. Michael Holers8, 1Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Japan, 2Tokyo Women's Medical University Division of Rheumatology, 10-22 Kawada-cho, Shinjyuku-ku, Tokyo, Japan, 3Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 4University of Colorado School of Medicine, Littleton, CO, 5University of Colorado Anschutz Medical Campus, Aurora, CO, 6Colorado School of Public Health, Aurora, CO, 7University of Colorado Denver, Denver, CO, 8University of Colorado, Denver, CO

    Background/Purpose: Production of autoantibodies following pathogenic T and B cell interactions precede the development of RA. T follicular helper (Tfh) cells and T peripheral helper…
  • Abstract Number: 1214 • ACR Convergence 2021

    Examining the Relationship Between Shared Epitope, ACPA Seropositivity, and Real-World Drug Effectiveness in Patients with Rheumatoid Arthritis

    Kristin Wipfler1, Joshua Baker2, Harlan Sayles3, Xue Han4, Sang Hee Park4, Keith Wittstock4, Ted Mikuls3 and Kaleb Michaud3, 1FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3University of Nebraska Medical Center, Omaha, NE, 4Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: The shared epitope (SE) is an amino acid sequence motif coded by several HLA-DRB1 alleles that are overrepresented among people with rheumatoid arthritis (RA).…
  • Abstract Number: 0033 • ACR Convergence 2021

    Impaired Adipose Tissue Function in Rheumatoid Arthritis: Association with Autoimmunity, Disease Activity and Therapeutic Response

    Iván Arias de la Rosa1, alejandro Escudero2, Cristobal Román-Rodriguez2, Rocio Guzmán-Ruiz2, Maria del Mar Malagón2, Carlos Pérez-Sánchez3, Chamaida Plasencia-Rodríguez4, Ana Martinez-Feito5, Maria del Carmen Ábalos-Aguilera2, Alejandra Patiño-Trives6, Jerusalem Calvo2, Rafaela Ortega2, Eduardo Collantes-Estevez2, Chary Lopez-Pedrera2 and Nuria Barbarroja1, 1University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, 2IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, 3IMIBIC, Córdoba, Spain, 4Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Rheumatology, La Paz University Hospital, Madrid, Spain, 5ImmunoRheumatology Department, IDIPAZ, Madrid, Spain, 6Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain

    Background/Purpose: 1) to evaluate the relationship among adipose tissue dysfunction, autoimmunity and disease activity in rheumatoid arthritis (RA) patients; 2) to analyze the direct effect…
  • Abstract Number: 1243 • ACR Convergence 2021

    Real World Validation of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis: Analysis from the RISE Registry

    Huifeng Yun1, Jeffrey Curtis2, Lang Chen3, cassie Clinton3, Hubert van Hoogstraten4, Stefano Fiore4, Markus Rehberg5 and Ernest Choy6, 1University of Alabama Birmingham, Birmingham, AL, 2Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Birmingham, AL, 4Sanofi, Bridgewater, NJ, 5Sanofi, Franfurt, Germany, 6CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom

    Background/Purpose: Accurately identifying patients who may respond better to a specific drug or mechanism of action could improve rational selection of medications to optimize clinical…
  • Abstract Number: 0034 • ACR Convergence 2021

    Immune Complexes Contain Novel Acetylated Antigens in the Synovial Fluid of RA Patients

    Khetam Ghannam1, Holger Bang2, Thomas Häupl1, Eugen Feist3 and Gerd Burmester4, 1Charite University Medicine Berlin, Berlin, Germany, 2Orgentec Diagnostika GmbH, Mainz, Germany, Mainz, Germany, 3Helios Department of Rheumatology, Vogelsang-Gommern, Germany, 4Charité University Medicine Berlin, Berlin, Germany

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by genetic predisposition and associated immunological features including the production of autoantibodies against various epitopes. Several…
  • Abstract Number: 1648 • ACR Convergence 2021

    Increasing Rates of Positivity of Autoantibodies Indicates a Shorter Time-to-Diagnosis of Future Rheumatoid Arthritis

    Dylan Bergstedt1, Ryan Peterson2, Marie Feser1, LauraKay Moss1, Geoffrey Thiele3, Ted Mikuls3, Jess Edison4, V. Michael Holers1 and Kevin Deane5, 1University of Colorado Denver, Aurora, CO, 2Colorado School of Public Health, Aurora, CO, 3University of Nebraska Medical Center, Omaha, NE, 4Walter Reed National Military Medical Center, Bethesda, MD, 5University of Colorado Denver, Denver, CO

    Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period that can be defined by elevations in autoantibodies to citrullinated protein antigens (ACPA) and rheumatoid factor (RF)…
  • Abstract Number: 0037 • ACR Convergence 2021

    Identification and Validation of Four Circulating Autoantibodies Associated with the ACPA Status in Early Rheumatoid Arthritis

    Lucía Lourido1, Cristina Ruiz-Romero2, Lidia Collado1, Monika Hansson3, Lars Klareskog4, Ronald Sjöberg5, Elisa Pin5, Peter Nilsson5 and Francisco Blanco-García6, 1Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España., A Coruña, Spain, 2Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Av. Monforte de Lemos, 3-5. Pabellón 11, 28029, Madrid, España., A Coruña, Spain, 3Division for Rheumatology, Karolinska Institutet, Stockholm, Sweden, 4Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 5Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology & SciLifeLab, Stockholm, Sweden, 6Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Universidade da Coruña (UDC), Grupo de Investigación de Reumatología y Salud (GIR-S). Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Fisioterapia, Campus de Oza, 15008, A Coruña, España., A Coruña, Spain

    Background/Purpose: The presence of anti-citrullinated protein antibodies (ACPAs) is a highly specific hallmark of rheumatoid arthritis (RA), that is present also in early disease. However,…
  • Abstract Number: 1652 • ACR Convergence 2021

    Symptom Burden in Anti-citrullinated Protein Antibody Positive Individuals At-risk for Rheumatoid Arthritis Is Changing over Time and Comparable to Patients with Early Rheumatoid Arthritis

    Paul Studenic1, Alexandra Circiumaru2, Daniel Aletaha3, Katerina Chatzidionysiou4, Anca Catrina5 and Aase Haj Hensvold6, 1Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, 2Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden, 3Medical University Vienna, Vienna, Austria, 4Karolinska Institute, Division of Rheumatology; & Karolinska University Hospital, Rheumatology Unit, Stockholm, Sweden, 5Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, 6Karolinska Institutet, Division for Rheumatology; & Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden

    Background/Purpose: Symptom burden in individuals at risk for developing rheumatoid arthritis (RA) - positive for anti-citrullinated peptide antibodies (ACPA) and musculoskeletal complaints - has not…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology